Intra-Cellular
Price
Price
CHART BY
Frequently asked questions
What is Intra-Cellular's market capitalization?
What is the Earnings Per Share (EPS) for Intra-Cellular?
What are the analyst ratings and target price for Intra-Cellular's stock?
What is Intra-Cellular's revenue over the trailing twelve months?
What is the free float of Intra-Cellular's shares?
Financials
- Market Cap
- $13.67B
- EPS (TTM)
- -$0.722
- Free Float
- 98.95M
- Revenue (TTM)
- $680.85M
Pricing
- 1D span
- $128.05$130.25
- 52W span
- $63.45$128.75
Analyst Ratings
The price target is $132.73 and the stock is covered by 12 analysts.
Buy
3
Hold
9
Sell
0
Information
Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company. It focuses on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS. The firm’s lead product candidate, ITI-007, is in clinical development as a first-in-class treatment for schizophrenia. It also includes pre-clinical programs that are focused on advancing drug candidates for the treatment of cognitive dysfunction, in both schizophrenia and Alzheimer's disease and for disease modification and the treatment of neurodegenerative disorders, including Alzheimer's disease. The company was founded by Paul Greengard and Sharon Mates in 2002 and is headquartered in Bedminster, NJ.
- Industries
- Major Pharmaceuticals
- Sector
- Health Care
Identifier
- ISIN
- US46116X1019
- Primary Ticker
- ITCI